Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells $537,100.00 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $53.71, for a total transaction of $537,100.00. Following the completion of the sale, the director directly owned 28,159 shares of the company’s stock, valued at $1,512,419.89. This trade represents a 26.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Georges Gemayel also recently made the following trade(s):

• On Friday, March 6th, Georges Gemayel sold 8,787 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00.

Supernus Pharmaceuticals Price Performance

SUPN traded up $0.30 during trading hours on Monday, reaching $54.17. 799,891 shares of the stock traded hands, compared to its average volume of 785,366. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -79.66, a PEG ratio of 1.67 and a beta of 0.70. The firm’s fifty day simple moving average is $50.99 and its two-hundred day simple moving average is $48.82.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Zacks Research cut Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Stifel Nicolaus lifted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SUPN. Hantz Financial Services Inc. grew its position in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares during the last quarter. Torren Management LLC bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $49,000. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at approximately $50,000. EverSource Wealth Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at about $51,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.